27
May
2021
GSK, Vir Win Antibody OK, Sanofi-GSK Moves to Phase III, & a Day One IPO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
May
2021
From Fitness To Flourish: Expanding the Scope of Digital Exercise
Sometimes the most relevant digital health companies have the least elaborate technology. More than a decade ago, I discussed UpToDate, a fairly basic medicine e-textbook, served through a web-based app. It was then, and still remains, a go-to site for timely, high-quality medical information relevant to clinicians. There’s nothing fancy about it, it just works. Recently, I discovered a similar... Read More